Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapies leveraging
CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative
company dedicated to developing optimally engineered natural killer
(NK) cell therapies to cure patients with cancer, today announced a
licensing and collaboration agreement. NK cells are specialized,
naturally occurring immune cells that play a critical role in
immune activation against abnormal cells, including cancer cells.
NK cells have gained significant attention in the field of cancer
immunotherapy and various approaches are being explored to
effectively develop and engineer NK cell-based cancer
immunotherapy.
The agreement grants ONK a non-exclusive license to Intellia’s
proprietary ex vivo CRISPR/Cas9-based genome editing platform and
its lipid nanoparticle (LNP)-based delivery technologies to develop
up to five allogeneic NK cell therapies. ONK will receive exclusive
rights to certain Intellia guide RNAs (gRNAs) resulting from the
collaboration for use in engineering those NK cell products. ONK
will be responsible for preclinical and clinical development for
the engineered NK cell therapies covered under the agreement.
Intellia will be eligible to receive up to $184 million per product
in development and commercial milestone payments, as well as up to
mid-single digit royalties on potential future sales. In addition,
the agreement grants Intellia options to co-develop and
co-commercialize up to two products worldwide with rights to lead
commercialization in the U.S. ONK retains lead commercialization
rights ex-U.S. This co-development and co-commercialization option
excludes ONK’s lead product ONKT-102, which is being developed for
the treatment of patients with relapsed / refractory multiple
myeloma, for which ONK retains sole rights. If Intellia chooses to
exercise the co-development and co-commercialization option on an
investigational product, in lieu of the potential royalties and
milestones, Intellia will share 50 percent of any future profit and
loss generated by the product.
“We look forward to working with ONK in the development of
allogeneic NK cell therapies for patients with cancer. This
collaboration, which combines Intellia’s industry-leading CRISPR
technology platform and ONK’s expertise in NK cell technology,
offers yet another powerful example of how we’re leveraging our
strategic collaborations to address life-threatening diseases for
patients in need,” said Intellia President and Chief Executive
Officer John Leonard, M.D.
“We believe combining Intellia’s ex vivo genome editing and LNP
delivery platforms with our suite of proprietary NK cell gene edits
has the potential to create optimally engineered NK cells with
enhanced cytotoxicity, persistence and an improved metabolic
profile that hold tremendous promise to advance the treatment of
both hematologic malignancies and solid tumors. We are excited to
partner with Intellia and are looking forward to a collaboration
that allows us to continue to deliver against our strategy, as we
evolve into a clinical-stage company,” said ONK Therapeutics Chief
Executive Officer Chris Nowers.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
leveraging CRISPR-based technologies. To fully realize the
transformative potential of CRISPR-based technologies, Intellia is
pursuing two primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
About ONK Therapeutics
ONK Therapeutics is an innovative cell therapy company dedicated
to developing the next generation of optimally engineered,
off-the-shelf, natural killer (NK) cell therapies. With a growing
pre-clinical pipeline targeting both hematological malignancies and
solid tumors, ONK is advancing multiple cell therapy candidates
towards the clinic, including its lead program, ONKT102, an
optimized affinity CD38 CAR-NK product, intended for the treatment
of patients with relapsed/ refractory multiple myeloma. Read about
the pipeline here.
The company’s optimally engineered NK cell therapy platform
utilizes a suite of proprietary gene edits and cell modification
strategies to optimize cytotoxic potential, persistence and the
metabolic health of NK cells, while reducing the potential for
their exhaustion in the tumor microenvironment. These include CISH
knockout (KO); the expression of high affinity, membrane bound,
TNF-related apoptosis-inducing ligand variants (TRAILv) targeting
DR5 or DR4; and the deletion of inhibitory receptors, including
extracellular proteins for example CD96, and Siglec-7. Read about
the platform here.
ONK Therapeutics is headquartered in the med-tech hub of Galway,
Ireland, with a wholly owned US subsidiary, ONK Therapeutics, Inc.
based at JLabs @ San Diego. Shareholders include Acorn Bioventures,
Cormorant Asset Management, ALSHC (principally Seamus Mulligan),
and Enterprise Ireland.
Learn more at www.onktherapeutics.com. Follow us on Twitter
@ONKTherapeutics and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding Intellia’s beliefs and expectations regarding:
its strategy, business plans and focus; its ability to quickly and
efficiently realize the scope and potential of its genome editing
technology; its ability to maintain, expand and maximize its
intellectual property portfolio and pipeline as well as accelerate
clinical validation for its platform, including through its
collaboration with ONK Therapeutics; the therapeutic value and
development potential of CRISPR/Cas9 genome editing technologies
and therapies; its ability to combine its CRISPR genome editing
platform with ONK Therapeutics’ natural killer (NK) cell therapy
platform to create successful therapeutic products; and the
expected strategic benefits of any current or future
collaborations, including the potential to generate revenue from
such collaborations and related products, including products
developed in collaboration with ONK Therapeutics.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks related to Intellia’s ability to protect and
maintain its intellectual property portfolio; risks related to
Intellia’s relationship with third parties, including its licensors
and licensees; risks related to the ability of Intellia’s licensors
to protect and maintain their intellectual property position;
uncertainties related to the authorization, initiation and conduct
of studies and other development requirements for the new company’s
product candidates; the risk that any one or more of the
collaboration product candidates will not be successfully developed
and commercialized; the risk that the results of preclinical
studies or clinical studies will not be predictive of future
results in connection with future studies; and the risk that
Intellia’s collaboration with ONK Therapeutics or its other
collaborations will not continue or will not be successful. These
and other risks and uncertainties are described in greater detail
in the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K and quarterly report on Form 10-Q filed
with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Intellia’s other
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release
represent Intellia’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date. Intellia explicitly disclaims any obligation to update any
forward-looking statements, except as required by law.
Contacts:
For Intellia:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com
For ONK:
International:Sue CharlesCharles Consultants+44
7968 726585sue@charles_consultants.com
Ireland:Ray GordonGordon MRM+353 87
2417373ray@gordonmrm.ie
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024